These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 35105476)

  • 1. Re: Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients with Localized Prostate Cancer: Results from the FLAME Randomized Phase III Trial.
    Walz J
    Eur Urol; 2022 May; 81(5):544-545. PubMed ID: 35105476
    [No Abstract]   [Full Text] [Related]  

  • 2. Patterns of Failure Following External Beam Radiotherapy With or Without an Additional Focal Boost in the Randomized Controlled FLAME Trial for Localized Prostate Cancer.
    Groen VH; Haustermans K; Pos FJ; Draulans C; Isebaert S; Monninkhof EM; Smeenk RJ; Kunze-Busch M; de Boer JCJ; van der Voort van Zijp J; Kerkmeijer LGW; van der Heide UA
    Eur Urol; 2022 Sep; 82(3):252-257. PubMed ID: 34953603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Standard whole prostate gland radiotherapy with and without lesion boost in prostate cancer: Toxicity in the FLAME randomized controlled trial.
    Monninkhof EM; van Loon JWL; van Vulpen M; Kerkmeijer LGW; Pos FJ; Haustermans K; van den Bergh L; Isebaert S; McColl GM; Smeenk RJ; Noteboom J; Walraven I; Peeters PHM; van der Heide UA
    Radiother Oncol; 2018 Apr; 127(1):74-80. PubMed ID: 29336835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Dose escalation in prostate cancer-standard dose versus dose escalation with simultaneous integrated boost to intraprostatic tumor formation: results from the FLAME Trial].
    Klautke G
    Strahlenther Onkol; 2022 Feb; 198(2):212-213. PubMed ID: 35037083
    [No Abstract]   [Full Text] [Related]  

  • 5. Cone beam CT-based dose accumulation and analysis of delivered dose to the dominant intraprostatic lesion in primary radiotherapy of prostate cancer.
    Tamihardja J; Cirsi S; Kessler P; Razinskas G; Exner F; Richter A; Polat B; Flentje M
    Radiat Oncol; 2021 Oct; 16(1):205. PubMed ID: 34702305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of androgen deprivation therapy on intraprostatic tumour volume identified on
    Chan J; Carver A; Brunt JN; Vinjamuri S; Syndikus I
    Br J Radiol; 2017 Mar; 90(1071):20160818. PubMed ID: 27993093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensity modulated high-dose-rate brachytherapy boost complementary to external beam radiation for intermediate- and high-risk localized prostate cancer patients--how we do it in Lübeck/Germany.
    Kovács G; Melchert C; Sommerauer M; Walden O
    Brachytherapy; 2007; 6(2):142-8. PubMed ID: 17434108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Failure patterns following external beam radiotherapy with or without additional focal boost in the randomized FLAME trial for localized prostate cancer].
    Spohn SKB; Grosu AL
    Strahlenther Onkol; 2022 Sep; 198(9):869-872. PubMed ID: 35579679
    [No Abstract]   [Full Text] [Related]  

  • 9. Simultaneous Integrated Radiotherapy Boost to the Dominant Intraprostatic Lesion: Final Results of a Phase I/II Trial.
    Buwenge M; Alitto AR; Cilla S; Capocaccia I; Mazzeo E; Ippolito E; Mantini G; Siepe G; Cavallini L; Valentini V; Deodato F; Morganti AG; Macchia G
    Anticancer Res; 2020 Nov; 40(11):6499-6503. PubMed ID: 33109589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re: Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer.
    Taneja SS
    J Urol; 2014 Apr; 191(4):983-5. PubMed ID: 24703117
    [No Abstract]   [Full Text] [Related]  

  • 11. Dose escalation using a hypofractionated, intensity-modulated radiation therapy boost for localized prostate cancer: preliminary results addressing concerns of high or low alpha/beta ratio.
    Shridhar R; Bolton S; Joiner MC; Forman JD
    Clin Genitourin Cancer; 2009 Oct; 7(3):E52-7. PubMed ID: 19815482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI.
    van Lin EN; Fütterer JJ; Heijmink SW; van der Vight LP; Hoffmann AL; van Kollenburg P; Huisman HJ; Scheenen TW; Witjes JA; Leer JW; Barentsz JO; Visser AG
    Int J Radiat Oncol Biol Phys; 2006 May; 65(1):291-303. PubMed ID: 16618584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion.
    Fonteyne V; Villeirs G; Speleers B; De Neve W; De Wagter C; Lumen N; De Meerleer G
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):799-807. PubMed ID: 18407430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypofractionated boost to the dominant tumor region with intensity modulated stereotactic radiotherapy for prostate cancer: a sequential dose escalation pilot study.
    Miralbell R; Mollà M; Rouzaud M; Hidalgo A; Toscas JI; Lozano J; Sanz S; Ares C; Jorcano S; Linero D; Escudé L
    Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):50-7. PubMed ID: 19910135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II multi-institutional clinical trial on a new mixed beam RT scheme of IMRT on pelvis combined with a carbon ion boost for high-risk prostate cancer patients.
    Marvaso G; Jereczek-Fossa BA; Vischioni B; Ciardo D; Giandini T; Hasegawa A; Cattani F; Carrara M; Ciocca M; Bedini N; Villa S; Morlino S; Russo S; Zerini D; Colangione SP; Panaino CMV; Fodor C; Santoro L; Pignoli E; Valvo F; Valdagni R; De Cobelli O; Orecchia R
    Tumori; 2017 May; 103(3):314-318. PubMed ID: 28009421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of focal radiotherapy boost for prostate cancer: radiation oncologists' perspectives and perceived barriers to implementation.
    Zhong AY; Lui AJ; Katz MS; Berlin A; Kamran SC; Kishan AU; Murthy V; Nagar H; Seible D; Stish BJ; Tree AC; Seibert TM
    Radiat Oncol; 2023 Nov; 18(1):188. PubMed ID: 37950310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous integrated boost to intraprostatic lesions using different energy levels of intensity-modulated radiotherapy and volumetric-arc therapy.
    Onal C; Sonmez S; Erbay G; Guler OC; Arslan G
    Br J Radiol; 2014 Feb; 87(1034):20130617. PubMed ID: 24319009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current standards and future directions for prostate cancer radiation therapy.
    Pinkawa M; Schoth F; Böhmer D; Hatiboglu G; Sharabi A; Song D; Eble MJ
    Expert Rev Anticancer Ther; 2013 Jan; 13(1):75-88. PubMed ID: 23259429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PROLAPSE: survey about local prostate cancer relapse salvage treatment with external beam re-irradiation: results of the Italian Association of Radiotherapy and Clinical Oncology (AIRO).
    Zerini D; Jereczek-Fossa BA; Ciabattoni A; Mirri A; Bertoni F; Fersino S; D'Agostino G; Lohr F; Mortellaro G; Triggiani L; Marvaso G; Pepa M; Cuccia F; Alongi F;
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2311-2317. PubMed ID: 32583236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of prostate cancer with intensity modulated radiation therapy (IMRT).
    Novaes P; Mottas RT; Lundgren M;
    Rev Assoc Med Bras (1992); 2015; 61(1):8-16. PubMed ID: 25909199
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.